Evidence map›Paper›PMID 7996443›Full record

ArticleThe Journal of pharmacology and experimental therapeutics1994

Antihypertensive effects of metformin in fructose-fed hyperinsulinemic, hypertensive rats.

S Verma, S Bhanot, J H McNeill

Registry-linked trialAbstract read
PubMed
In one paragraph

Article in The Journal of pharmacology and experimental therapeutics, 1994. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04626089 (Adaptive Study for Efficacy and Safety of Metformin Glycinate for the Treatment of Patients With MS and DM2, Hospitalized With Severe Acute Respiratory Syndrome Secondary to SARS-CoV-2. Randomized, Double-Blind, Phase IIIb.), which is not on this map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
4.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04626089 phase2withdrawnstarted 2021, after this paper: background citation

Adaptive Study for Efficacy and Safety of Metformin Glycinate for the Treatment of Patients With MS and DM2, Hospitalized With Severe Acute Respiratory Syndrome Secondary to SARS-CoV-2. Randomized, Double-Blind, Phase IIIb.

Ran2021Enrolled0Registered outcomes12Posted comparisons0ConditionsMetabolic Syndrome, Severe Acute Respiratory Syndrome Coronavirus 2, Type 2 DiabetesArmsMetformin glycinate, Placebo Oral Tablet
PMID 30414960PMID 22974412PMID 17941868PMID 9030834PMID 19538242PMID 7623903PMID 19918015PMID 8269798PMID 2648723PMID 12086935PMID 20577053PMID 16308421other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 129 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Beneficiary effect ofJournal of traditional and complementary medicine · 2018
    Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Lipoic acid attenuates hypertension and improves insulin sensitivity, kallikrein activity and nitrite levels in high fructose-fed rats.Journal of comparative physiology. B, Biochemical, systemic, and environmental physiology · 2004
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

S VermaDivision of Pharmacology and Toxicology, Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, Canada.
S Bhanot
J H McNeill
University of British Columbia · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the present study, we examined the relationship between elevated insulin levels and hypertension in the fructose-hypertensive rat model, in which the rise in blood pressure is induced by feeding normal rats a fructose-enriched diet. Six-week-old Sprague-Dawley rats were divided into four experimental groups: control (C, n = 8), control metformin-treated (CT, n = 8), fructose-fed (F, n = 9) and fructose-fed, metformin-treated (FT, n = 10). Long-term oral metformin treatment (500 mg/kg/day) was begun in the CT and FT groups, and 1 week after the initiation of metformin treatment, the F and FT groups started receiving a 66% fructose diet. Metformin treatment prevented the increase in plasma insulin levels in the FT rats (FT, 32 +/- 4 microU; F, 51 +/- 7 microU-ml; P < .001) without any change in plasma glucose levels. Interestingly, metformin treatment also prevented the increase in systolic blood pressure in the FT group (FT, 143 +/- 2 mm Hg; F, 159 +/- 2 mm Hg; P < .001) but had no effect in the CT group (CT, 142 +/- 3 mm Hg; versus C, 141 +/- 2 mm Hg; P > .05). Restoration of plasma insulin levels in the FT group to levels that existed in the untreated F rats reversed the effect of metformin on blood pressure (FT plus insulin, 158 +/- 3 mm Hg; F, 160 +/- 3 mm Hg; P > .05). In conclusion, metformin prevents the hyperinsulinemia and hypertension that occur after feeding normal rats a fructose-enriched diet. Also, the antihypertensive effects of metformin can be reversed by raising the plasma insulin levels in the treated rats to those that exist in the untreated fructose-fed group, which suggests that hyperinsulinemia may contribute toward the increase in blood pressure in this model of experimental hypertension.

Indexed as

AnimalsAntihypertensive AgentsBlood PressureDisease Models, AnimalFructoseHypertensionInsulinMaleMetforminRatsRats, Sprague-DawleyAntihypertensive AgentsFructoseInsulinMetformin

Identifiers

PMID7996443
OpenAlexW1826960592

What Socratic holds

Texttitle and abstract
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.